DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hs3g9q/us_generic_drug) has announced the addition of the "US Generic Drug Market Outlook 2018" report to their offering.
The US Generics market, which was US$ 43.5 Billion in 2013, is anticipated to grow at a CAGR of around 11% during 2013-2018
The US is the largest pharmaceutical market in the world. Driven by the factors such as large healthcare spending, high per-capita income, and strong research & development investments, the pharmaceutical market in the US has witnessed an upward surge over the past few years. Additionally, the share of Generics has increased steadily in the pharmaceutical market, in terms of both revenue and prescriptions.
The US generic drugs market accounts for a share of around 45% in the global Generics market. This share has been growing at a fast pace on the back of factors, such as demand for cost-effective medications, rising healthcare expenditure, increasing aging population, patent expiration of blockbuster drugs, and enhanced government support. Besides, factors such as surging drug prices, lack of FDA support, long product approval process, and legal controversies related to drug approvals are holding back growth in the Generics industry.
Currently, the market is witnessing significant developments in terms of new product categories that are attracting huge investments from both public and private players. The Generics market in the US will showcase a healthy growth potential in various therapy segments, such as oncology, respiratory, thyroid, ulcers as well as cholesterol disorders in the coming years. Growth in the aforementioned segments will be the result of patent expirations of a number of the major drugs in the next few years. The support from the US government in the form of approvals and incentives, will also act as a catalyst for future growth in the generic domain.
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. Market Drivers
4. Market Challenges
5. Overview of Generics Sector
6. Market Potential for Generic Drugs in Key Therapies Segments
7. Market Trends & Developments
8. Regulatory Environment
9. Competitive Landscape
- Actavis Plc
- Amneal Pharmaceuticals
- Dr. Reddy's Laboratories Ltd.
- Endo International Plc.
- Lupin Limited
- Mylan Inc.
- Pfizer Inc.
- Sandoz Inc. (Novartis)
- Teva Pharmaceuticals USA
- Zydus Pharmaceuticals Inc.
For more information visit http://www.researchandmarkets.com/research/hs3g9q/us_generic_drug